CytomX Therapeutics Reports Q2 2024 Financial Results
Intellectia.AI1970-01-01
CytomX Therapeutics Reports Q2 2024 Financial Results
CytomX Therapeutics, Inc. (NASDAQ: CTMX), a leader in the development of masked, conditionally activated biologics, reported its financial results for the second quarter ending June 30, 2024.
Key Financial Metrics
| Metric | Q2 2023 | Q2 2024 | YoY Change | Analyst Estimates | Performance vs. Estimates |
|---|---|---|---|---|---|
| Total Revenue | $24.7 million | $25.1 million | +1.6% | $19.99 million | Above |
| Earnings per Share (EPS) | N/A | N/A | N/A | -$0.14 | N/A |
Analysis: CytomX generated $25.1 million in total revenue during Q2 2024, a year-over-year increase of 1.6% from $24.7 million in Q2 2023. This revenue surpasses analyst estimates of $19.99 million. EPS was not provided for comparison.
Revenue Performance by Segment
| Segment | Q2 2023 | Q2 2024 | Previous Guidance | Performance vs. Guidance |
|---|---|---|---|---|
| Regeneron Collaboration | N/A | N/A | N/A | N/A |
| Moderna Collaboration | N/A | N/A | N/A | N/A |
Analysis: Details pertaining to segment revenue figures or previous guidance were not disclosed in the earnings release; thus, an in-depth comparison is unavailable.
Comments from Company Officers
"We are encouraged by the initial CX-904 Phase 1a data we shared in the second quarter that demonstrated single agent anti-cancer activity and a favorable therapeutic window for the high potential and previously undruggable target combination of EGFR and CD3, underscoring the potential of our PROBODY therapeutic platform," stated CEO and Chairman Sean McCarthy, D.Phil. He also noted that patient enrollment for CX-904 would now focus primarily on pancreatic, non-small cell lung, and head and neck cancers.
Dividends and Share Repurchase Program
Information regarding any dividends or share repurchase programs was not mentioned in the earnings release.
Forward Guidance
CytomX has provided the following guidance: - CX-904: Future updates expected by the end of 2024. - CX-2051: Initial data expected in the first half of 2025. - CX-801: Initial data anticipated in the second half of 2025.
Stock Price Movement
Following the earnings release, CytomX saw a 1.72% increase in its stock price.
Summary: CytomX Therapeutics reported Q2 2024 revenue exceeding analyst expectations, driven mainly by collaboration milestones. The company continues to make strides in its clinical trials and expects to share more data on its pipeline projects in the coming quarters. The stock showed a positive reaction with an increase in the stock price post-announcement.
Share